Topic: Manufacturing Facilities
WuXi Biologics has inked a deal to build its first U.S. manufacturing facility in Worcester, Massachusetts, at a 46-acre biomanufacturing hub.
It's never a good idea to shred documents and mislead FDA investigators during an inspection, and India's Windlas Healthcare could soon learn why.
Pharming Group has gained approvals for a new biologics manufacturing facility that will ensure it has sufficient supplies of its HAE drug.
An FDA warning letter has been issued to Cipla's sterile injectables plant in Goa after inspectors found big problems with cleanliness.
An OTC maker that was once cited for selling unapproved suppositories has now been issued a warning letter for having dirty equipment.
Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.
North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina.
Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.
Takeda says will sell a $400 million biologics plant in Ireland that it picked up in its buyout of Shire but says it does not need.
WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.